Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

The Future of Longevity: AI and Nanorobots to Radically Extend Life

by Team Lumida
June 25, 2024
in AI, Health and Longevity
Reading Time: 3 mins read
A A
0
person holding black and white microscope

Photo by Jaron Nix on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

  1. AI-driven drug discovery could drastically cut down clinical trial times.
  2. Medical nanorobots may revolutionize immune systems by the 2030s.
  3. By 2040s, mind-backup systems might allow near-immortality.

What Happened?

Futurist Ray Kurzweil claims that AI will revolutionize drug discovery and medical interventions by the end of the 2020s. He believes biological simulators will soon generate crucial safety and efficacy data in hours, not years.

This shift could lead to faster drug approvals and save countless lives. Kurzweil also predicts that medical nanorobots will emerge in the 2030s, vastly enhancing our immune systems and treating metabolic diseases. By 2040s, he envisions mind-backup systems that could essentially render death obsolete.

Why It Matters?

These advancements could disrupt traditional medical models and extend human lifespans dramatically. Faster drug approvals would mean quicker access to lifesaving treatments. Medical nanorobots could address diseases that our natural immune systems can’t, such as cancer and neurodegenerative disorders.

The potential to back up our minds might lead to radical life extension, fundamentally changing the concept of mortality. Investors should note the profound implications for the healthcare and biotech sectors, which could experience exponential growth.

What’s Next?

Expect increased investment in AI-driven pharmaceutical research and biotech firms focused on nanotechnology. Regulatory landscapes will evolve to accommodate simulated trials, despite potential bureaucratic resistance. By the mid-2040s, mind-backup technologies will likely face ethical and security challenges, but Kurzweil is optimistic about overcoming these hurdles.

As these technologies become mainstream, they will likely follow the trajectory of the cell phone—starting expensive and exclusive, but eventually becoming widely accessible.

Source: Fortune Well
Tags: AI-driven drug discoverymedical nanorobotsmind-backup systemsRay Kurzweil
Previous Post

Bitcoin Crashes to $62K: What’s Behind the $150M Liquidation?

Next Post

TikTok Ban Could Dent Oracle’s Earnings: What Investors Need to Know

Recommended For You

Waymo Hits 10 Million Rides, Leading the Driverless Revolution

by Team Lumida
23 hours ago
a car that is driving down the street

Key Takeaways: Powered by lumidawealth.com Waymo, Google’s autonomous taxi service, has surpassed 10 million paid rides, with exponential growth expected to reach 20 million by the end of 2025....

Read more

EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

by Team Lumida
2 days ago
EssilorLuxottica Acquires AI-Driven Ophthalmology Platform Optegra to Expand Medical Technology Portfolio

Key Takeaways: Powered by lumidawealth.com EssilorLuxottica, the maker of Ray-Ban, announced plans to acquire Optegra, an AI-focused ophthalmology platform operating over 70 eye hospitals across Europe. The acquisition aligns...

Read more

Delaware AG Seeks Investment Bank to Advise on OpenAI Restructuring Amid Legal and Regulatory Scrutiny

by Team Lumida
3 days ago
AI Security Breach: How Hackers Stole OpenAI’s Internal Secrets

Key Takeaways: Powered by lumidawealth.com Delaware Attorney General Kathy Jennings plans to hire an investment bank to advise on OpenAI’s restructuring and conduct an independent valuation of its assets....

Read more

Nvidia Posts Record $44 Billion Revenue Despite China Ban, Shares Surge Over 5%

by Team Lumida
3 days ago
Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Key Takeaways: Powered by lumidawealth.com Nvidia’s Q1 revenue reached a record $44.06 billion, a 69% year-over-year increase, despite losing $2.5 billion in sales due to U.S. restrictions on chip...

Read more

We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

by Team Lumida
4 days ago
We Made a Film With AI: Revolutionary Tools, Human Creativity, and a Lot of Work- WSJ

Key Takeaways: Powered by lumidawealth.com Using AI tools like Google’s Veo 3 and Runway AI, WSJ producers created a three-minute film, “My Robot & Me,” entirely with AI-generated visuals...

Read more

Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

by Team Lumida
5 days ago
Capgemini Partners with SAP and Mistral AI to Deliver Generative AI Solutions for Regulated Industries

Key Takeaways: Powered by lumidawealth.com Capgemini has teamed up with Mistral AI and SAP to provide generative AI-powered solutions tailored for regulated industries. The collaboration leverages Mistral AI’s advanced...

Read more

OpenAI Expands to South Korea, Citing Strong AI Adoption and Market Potential

by Team Lumida
6 days ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways: Powered by lumidawealth.com OpenAI has established a legal entity in South Korea and plans to open an office in Seoul in the coming months to support partnerships...

Read more

DOJ Probes Google’s Deal with Character.AI for Potential Antitrust Violations

by Team Lumida
1 week ago
China Stimulus: Enough to Sway Markets?

Key Takeaways: The U.S. Department of Justice (DOJ) is investigating whether Google’s licensing agreement with Character.AI violates antitrust laws by circumventing formal government merger scrutiny. Google signed a...

Read more

Sam Altman and Jony Ive Unveil Plans for AI-Powered ‘Companion’ Device

by Team Lumida
1 week ago
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

Key Takeaways: Powered by lumidawealth.com OpenAI plans to launch a pocket-sized, screen-free AI "companion" device by late 2026, aiming to integrate AI seamlessly into everyday life. The device, designed...

Read more

Nvidia CEO Criticizes U.S. AI Export Curbs, Calls for Easing Restrictions on China

by Team Lumida
2 weeks ago
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Key Takeaways: Powered by lumidawealth.com Nvidia CEO Jensen Huang criticized U.S. export controls on AI chips, calling them a "failure" and urging the White House to ease restrictions to...

Read more
Next Post
a red cube with white text

TikTok Ban Could Dent Oracle's Earnings: What Investors Need to Know

a person holding a phone

AI and Crypto Shakeup: Nvidia and Bitcoin's Massive Drops Explained

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a low angle view of a building

Tencent’s Profit Booms: Domestic Gaming Revenue Back in Action!

August 14, 2024
blue coupe parked beside white wall

Elon Musk Reassures Tesla Employees Amid Stock Slump and Political Backlash

March 21, 2025
flag hanging on pole

JPMorgan’s $40 Billion Indian Bond Bet:

June 20, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018